By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
INTRODUCTION
Treatments for itchy, puffy, and irritated skin involve mometasone. They can aid in treating psoriasis and various forms of eczema, such as atopic dermatitis and seborrheic dermatitis. Only on prescription are mometasone skin treatments available.
Treatment for fungal skin infections include eczema, psoriasis, ringworm, athlete’s foot, jock itch, dermatitis, and tinea versicolor involves the use of MOMETASONE FUROATE+TERBINAFINE HYDROCHLORIDE.
A steroid drug is mometasone. The chemical messengers (prostaglandins) that cause the skin to become irritated, puffy, and red are prevented from being produced. By preventing fungus from developing their own protective layer, the antifungal terbinafine slows the growth of fungi.
GLOBAL TERBINAFINE MOMETASONE MARKET SIZE AND FORECAST
The Global terbinafine mometasone market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
NEW PRODUCT LAUNCH
ClaroTM, a new single-dose medication from Bayer, is available to treat canine otitis externa (florfenicol, terbinafine, mometasone furoate) Otic Solution offers vets a first-line treatment that is efficient and does not require pet owners to administer it at home. Inc.
Bayer HealthCare ClaroTM (15.0 mg/mL florfenicol, 13.3 mg/mL terbinafine, and 2.0 mg/mL mometasone furoate) Otic Solution, the first single-dose medication demonstrated to effectively treat susceptible strains of common infections prevalent in canine otitis externa, has been approved by Animal Health. This month, the product is anticipated to be sold only to veterinarians.
Otitis externa may be a frustrating condition for both canine patients and their owners and is the second most frequent reason dog owners bring their pet to the doctor.
The illness is an ear canal irritation that frequently has subsequent infections as a side effect. It often necessitates client administration of ear treatments at home and frequently results in pain, itching, a strong odour, and/or muted hearing in affected dogs.
The goal of Claro is to serve as a first-line treatment for otitis externa that meets the requirements of both dog owners and veterinarians. It is a single, veterinarian-administered treatment that is a clear liquid solution with a predetermined combination of antibacterial, antifungal, and anti-inflammatory chemicals.
The innovative single-dose treatment regimen removes the veterinarian’s ambiguity regarding pet owner compliance and spares pet owners the difficulties of at-home administration and several treatment visits. Claro was created by Piedmont Animal Health in Greensboro, North Carolina, in collaboration with Bayer.
COMPANY PROFILE
THIS REPORT WILL ANSWER FOLLOWING QUESTIONS
